Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 22NIH 6NETWORK 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 230Breast Neoplasms 187Ovarian Neoplasms 113Neoplasms 100Neoplasm Metastasis 59Lung Neoplasms 54Fallopian Tube Neoplasms 47Triple Negative Breast Neoplasms 44Stomach Neoplasms 41Parkinson Disease 4, Autosomal Dominant Lewy Body 41Endometrial Neoplasms 37Carcinoma, Ovarian Epithelial 32Squamous Cell Carcinoma of Head and Neck 28Uterine Cervical Neoplasms 24Esophageal Neoplasms 21Carcinoma 21Colorectal Neoplasms 20Recurrence 19Melanoma 18Esophageal Squamous Cell Carcinoma 18Small Cell Lung Carcinoma 16Pancreatic Neoplasms 16Head and Neck Neoplasms 14Solid Tumors 12Adenocarcinoma 12Advanced Solid Tumors 11Carcinoma, Renal Cell 10Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8Solid Tumor 8

Interventions

Fluorouracil 12pembrolizumab 9Oxaliplatin 9Nivolumab 9Leucovorin 8Capecitabine 7Cisplatin 6Trastuzumab 4Paclitaxel 3Drug Therapy 3Docetaxel 3zimberelimab 2zanidatamab 2tucatinib 2spartalizumab 2durvalumab 2Radiotherapy 2Levoleucovorin 2Irinotecan 2Gemcitabine 2Carboplatin 2130-nm albumin-bound paclitaxel 2zolbetuximab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1tezacitabine 1ribociclib 1quemliclustat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma Of Esophagus × Paclitaxel × Clear all
NCT05954312 2026-05-08

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Vividion Therapeutics, Inc.

Phase 1 Recruiting
290 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasms

NCT06356311 2026-02-27

TroFuse-015

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04499924 2025-01-22

MOUNTAINEER-02

Seagen Inc.

Phase 2/3 Completed
17 enrolled 23 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡